Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents-Reference-Cited by-同舟云学术

Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents

Published:2020-07-28 Issue:10 Volume:59 Page:1195-1216
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Zeitlinger Markus^ORCID,Koch Birgit C. P.,Bruggemann Roger,De Cock Pieter,Felton Timothy,Hites Maya,Le Jennifer,Luque Sonia,MacGowan Alasdair P.,Marriott Deborah J. E.,Muller Anouk E.,Nadrah Kristina,Paterson David L.,Standing Joseph F.,Telles João P.,Wölfl-Duchek Michael,Thy Michael,Roberts Jason A.,

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40262-020-00924-9.pdf

Reference102 articles.

1. Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397–412.

2. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.

3. Liverpool Uo. Covid-19 drug interactions. https://www.covid19-druginteractionsorg/. Accessed 17 July 2020.

4. WHO. Global research on coronavirus disease (COVID-19). https://www.whoint/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov. Accessed 17 July 2020.

5. Elsevier. Clinical Pharmacology. https://www.clinicalpharmacologycom/. Accessed 17 July 2020.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of nafamostat and camostat mesylate randomised clinical trials;Clinical Microbiology and Infection;2024-02

2. Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention;Stem Cells;2024

3. Secondary Infections in Patients with Extremely Severe COVID-19 During ECMO Therapy;General Reanimatology;2023-04-26

4. Multi-Targeting Approach in Selection of Potential Molecule for COVID-19 Treatment;Viruses;2023-01-12

5. Modulating Immune Response in Viral Infection for Quantitative Forecasts of Drug Efficacy;Pharmaceutics;2023-01-03